» Articles » PMID: 26770249

Primary Neuroendocrine Carcinoma of the Breast with Clinical Features of Inflammatory Breast Carcinoma: A Case Report and Literature Review

Overview
Journal J Breast Cancer
Date 2016 Jan 16
PMID 26770249
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Primary neuroendocrine carcinoma of the breast (NECB) is a very rare type of invasive breast carcinoma. Most NECBs appear on breast imaging as solid masses of varied shapes and margins, and have worse clinical outcomes than does invasive ductal carcinoma, not otherwise specified. However, there have been no reports to date regarding NECB with features of inflammatory breast carcinoma. Here, we describe the clinical, radiol-ogic, and pathologic findings of the first reported case of primary NECB presenting as inflammatory breast carcinoma. The patient complained of diffuse right breast enlargement and erythema. Mammography identified severe breast edema and axillary lymphadenopathy. Ultrasound detected an irregular, angular, hypoechoic mass with dermal lymphatic dilatation. On magnetic resonance imaging, the mass had rim enhancement and the entire right breast showed heterogeneous enhancement with malignant kinetic features. Pathology identified the mass as a primary NECB with positive for synaptophysin, CD56, estrogen and progesterone receptors.

Citing Articles

CDK4/6 and aromatase inhibitors as first-line treatment in metastatic high-grade neuroendocrine carcinoma of the breast: A case report.

Zouki D, Kardara V, Ioannou S, Arvanitou E, Exarchos K, Gkikas K Clin Case Rep. 2024; 12(7):e9180.

PMID: 39021492 PMC: 11252434. DOI: 10.1002/ccr3.9180.


Primary neuroendocrine carcinoma of the breast: a rare presentation and review of the literature.

Salemis N Intractable Rare Dis Res. 2020; 9(4):233-246.

PMID: 33139983 PMC: 7586876. DOI: 10.5582/irdr.2020.03046.


Dramatic response to cyclin D-dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast.

Shanks A, Choi J, Karur V Proc (Bayl Univ Med Cent). 2018; 31(3):352-354.

PMID: 29904310 PMC: 5997053. DOI: 10.1080/08998280.2018.1463041.

References
1.
Zhang Y, Chen Z, Bao Y, Du Z, Li Q, Zhao Y . Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 Chinese patients. Neoplasma. 2012; 60(2):215-22. DOI: 10.4149/neo_2013_029. View

2.
Gunhan-Bilgen I, Zekioglu O, Ustun E, Memis A, Erhan Y . Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol. 2003; 13(4):788-93. DOI: 10.1007/s00330-002-1567-z. View

3.
Kim J, Woo O, Cho K, Seo B, Yong H, Kim A . Primary large cell neuroendocrine carcinoma of the breast: radiologic and pathologic findings. J Korean Med Sci. 2009; 23(6):1118-20. PMC: 2610652. DOI: 10.3346/jkms.2008.23.6.1118. View

4.
Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F . Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer. 2010; 116(19):4463-73. DOI: 10.1002/cncr.25352. View

5.
Ochoa R, Sudhindra A, Garcia-Buitrago M, Romilly A, Cortes J, Gomez H . Small-cell cancer of the breast: what is the optimal treatment? A report and review of outcomes. Clin Breast Cancer. 2012; 12(4):287-92. DOI: 10.1016/j.clbc.2012.03.007. View